NO991425L - Medisinsk behandling - Google Patents

Medisinsk behandling

Info

Publication number
NO991425L
NO991425L NO991425A NO991425A NO991425L NO 991425 L NO991425 L NO 991425L NO 991425 A NO991425 A NO 991425A NO 991425 A NO991425 A NO 991425A NO 991425 L NO991425 L NO 991425L
Authority
NO
Norway
Prior art keywords
medical treatment
hyperuricaemia
methylbutyl
monohydrate
cyclobutyl
Prior art date
Application number
NO991425A
Other languages
English (en)
Other versions
NO991425D0 (no
Inventor
Peter Finian Kelly
Stephen Paul Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of NO991425L publication Critical patent/NO991425L/no
Publication of NO991425D0 publication Critical patent/NO991425D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Forbindelse med formel l CH3 H3CCHCH2CHNR,R, eller et farmasøytisk akseptabelt salt derav hvor Ri og R2 er uavhengig H eller metyl (for eksempel A/,tø-dimetyl-1-[1-(4-klorfenyl)cyklobutyl]-3-metylbutyl- amin- hydroklorid, eventuelt i form av dets monohydrat) blir anvendt for senking av urinsyrenivået hos mennesker, for eksempel hos mennesker som lider av eller med risiko for utvikling av gikt, hyperuricaemi eller koronar hjertesykdom.
NO991425A 1996-09-25 1999-03-24 Medisinsk behandling NO991425D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619962.5A GB9619962D0 (en) 1996-09-25 1996-09-25 Medical treatment
PCT/EP1997/005034 WO1998013033A1 (en) 1996-09-25 1997-09-15 Medical treatment

Publications (2)

Publication Number Publication Date
NO991425L true NO991425L (no) 1999-03-24
NO991425D0 NO991425D0 (no) 1999-03-24

Family

ID=10800448

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991425A NO991425D0 (no) 1996-09-25 1999-03-24 Medisinsk behandling

Country Status (26)

Country Link
US (1) US6162831A (no)
EP (1) EP1007023B1 (no)
JP (1) JP2001501608A (no)
KR (1) KR20000048568A (no)
CN (1) CN1231604A (no)
AT (1) ATE239460T1 (no)
AU (1) AU722129B2 (no)
BG (1) BG103278A (no)
BR (1) BR9711414A (no)
CA (1) CA2266438A1 (no)
DE (1) DE69721838T2 (no)
DK (1) DK1007023T3 (no)
ES (1) ES2199374T3 (no)
GB (1) GB9619962D0 (no)
HR (1) HRP970519A2 (no)
HU (1) HUP9904545A3 (no)
IL (1) IL128851A (no)
NO (1) NO991425D0 (no)
NZ (1) NZ334668A (no)
PL (1) PL332423A1 (no)
PT (1) PT1007023E (no)
SK (1) SK32199A3 (no)
TR (1) TR199900649T2 (no)
TW (1) TW415842B (no)
WO (1) WO1998013033A1 (no)
ZA (1) ZA978573B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
EP1169027A4 (en) * 1999-03-19 2004-10-20 Abbott Gmbh & Co Kg TREATMENT OF ARTHROSIS
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
US9655932B2 (en) * 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
NZ538966A (en) * 2002-10-05 2006-11-30 Hanmi Pharm Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
JP2008506785A (ja) * 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド インスリン抵抗性の治療及び予防のための組成物及び方法
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
WO2018125735A1 (en) 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
KR20210124958A (ko) * 2018-11-02 2021-10-15 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment

Also Published As

Publication number Publication date
HRP970519A2 (en) 1998-08-31
HUP9904545A2 (hu) 2000-11-28
SK32199A3 (en) 1999-12-10
CA2266438A1 (en) 1998-04-02
IL128851A (en) 2001-08-26
PL332423A1 (en) 1999-09-13
DE69721838D1 (de) 2003-06-12
DE69721838T2 (de) 2004-01-22
GB9619962D0 (en) 1996-11-13
AU722129B2 (en) 2000-07-20
EP1007023A1 (en) 2000-06-14
TR199900649T2 (xx) 1999-07-21
BG103278A (en) 2000-01-31
HUP9904545A3 (en) 2000-12-28
ATE239460T1 (de) 2003-05-15
US6162831A (en) 2000-12-19
WO1998013033A1 (en) 1998-04-02
DK1007023T3 (da) 2003-08-25
TW415842B (en) 2000-12-21
PT1007023E (pt) 2003-08-29
NO991425D0 (no) 1999-03-24
BR9711414A (pt) 2000-04-25
JP2001501608A (ja) 2001-02-06
ES2199374T3 (es) 2004-02-16
AU4385197A (en) 1998-04-17
NZ334668A (en) 2000-07-28
CN1231604A (zh) 1999-10-13
KR20000048568A (ko) 2000-07-25
ZA978573B (en) 1999-03-25
IL128851A0 (en) 2000-01-31
EP1007023B1 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
NO991425L (no) Medisinsk behandling
NO168771C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse 11-(4-(2-(2-hydroksyetoksy)etyl)-1-piperazinyl)dibenzo(b,f)-(1,4)-tiazepin og farmasoeytisk akseptable salter derav
ZA95814B (en) Medical treatment
ID21775A (id) Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
NO971471L (no) Nye karboksamider med fungicid aktivitet
FI933391A0 (fi) Triazolyltiometyltio-cefalosporin-hydroklorid, dess kristalliserad hydrat samt foerfarande foer deras framstaellning
IL177626A0 (en) Pharmaceutical compositions for treating sleep apnoea
DE60220055D1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
NZ220779A (en) 4-(aroylamino) piperidine butanamides, intermediates, and compositions
EP0266559A3 (en) Therapeutic agent for the treatment of peptic ulcer disease
NO983453L (no) Fremgangsmåte for ökning av sfinkterfunksjon
AU2002354850A1 (en) 4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
ATE44875T1 (de) 4-amino-2-(imidazolidin-2-on-l-yl)-pyrimidin-5carbons|ure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln.
RU99108729A (ru) Способ лечения
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása
TH18470A (th) อนุพันธ์เมลาโทนินสำหรับใช้ในการรักษาความผิดปกติของการหลับ
IT1271412B (it) Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare